Immunomedics Inc
Change company Symbol lookup
Select an option...
IMMU Immunomedics Inc
VLAAX Value Line Asset Allocation Fund Investor Class
DODBX Dodge & Cox Balanced Fund
JABAX Janus Henderson Balanced Fund Class T
JBALX Janus Henderson Balanced Fund Class I
ARSVX AMG River Road Small Cap Value Fund Class N
ARSMX AMG River Road Small-Mid Cap Value Fund Class N
TSCSX Thrivent Small Cap Stock Fund Class S
AASMX Thrivent Small Cap Stock Fund Class A
STON StoneMor Partners LP
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Closing Price
$14.80
Day's Change
0.37 (2.56%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.83
Day's Low
14.43
Volume
(Light)
Volume:
1,538,633

10-day average volume:
2,442,649
1,538,633
  • Prev Close
    14.43
  • Today's Open
    14.52
  • Day's Range
    14.43-14.83
  • Avg Vol (10-day)
    2.4M
  • Last (time)
    4:00p ET 05/24/19
  • Last (size)
    52
  • 52-Wk Range
    11.55 - 27.33
    LowHigh
  • (07/18/18 - 01/18/19)
    28.14%
  • 65.8%
  • Market Cap
    2.8B
  • Shares Outstanding
    191.5M
  • -1.38
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 2.0
  • 91.56
  • (% of float 05/15/19)
    18.33

Latest News

May 09, 2019
7:03 am ET
Globe Newswire
May 07, 2019
8:07 am ET
Globe Newswire
May 02, 2019
1:21 pm ET
MarketWatch
8:13 am ET
Globe Newswire
April 29, 2019
7:40 am ET
Globe Newswire
7:35 am ET
Globe Newswire
April 08, 2019
8:59 am ET
Globe Newswire
March 27, 2019
9:00 am ET
PR Newswire
March 07, 2019
4:01 pm ET
Globe Newswire
March 05, 2019
9:00 am ET
PR Newswire
March 04, 2019
7:59 am ET
Globe Newswire
March 01, 2019
8:34 am ET
Globe Newswire
February 26, 2019
8:32 am ET
Globe Newswire
February 25, 2019
5:54 pm ET
Globe Newswire
4:00 pm ET
Globe Newswire
2:19 pm ET
Globe Newswire
February 24, 2019
10:50 pm ET
BusinessWire
6:05 pm ET
Globe Newswire
January 22, 2019
12:43 pm ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.